Evommune, Inc. (EVMN)

NYSE Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$49.7M
Cash & Equivalents
$27.5M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$476M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (3)

NCT #TitlePhaseStatusEnrollment
NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis PHASE2 Active Not Recruiting 120
NCT07616128 Study of EVO756 in Adults With Migraine PHASE2 Recruiting 330
NCT06645821 Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% PHASE1 Recruiting 15

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for EVMN.

SEC EDGAR Filings

All SEC filings for Evommune, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.